Finally, many clinical trials are currently testing drugs that inhibit CRMP2 phosphorylation, as CRMP2 is involved in various neurological disorders (Alzheimer’s disease, schizophrenia, cephalic pain, etc.)19. The gene discussed is DPYSL2; the disease is early-onset autosomal dominant Alzheimer disease.